Announces Strategy to Accelerate Efforts Toward
Ending the TB Pandemic
BALI,
Indonesia, Nov. 11, 2024 /PRNewswire/ -- TB Alliance
is honored to join today's High-Level Meeting hosted by the
Indonesian Ministry of Health. Leaders and experts in tuberculosis
(TB) have convened to discuss strategies, innovations, and
achievements in the global fight to end TB. The full-day session
will bring together a distinguished group of global stakeholders
dedicated to addressing and eliminating the TB pandemic.
The meeting will feature a series of expert panels that will
delve into comprehensive analyses of the current state of TB,
alongside forward-looking strategies that prioritize groundbreaking
solutions in treatment, diagnostics, and vaccine development.
Representing TB Alliance, Dr. Mel
Spigelman, President and CEO, Dr. Eugene Sun, Senior Vice President of R&D,
and Sandeep Juneja, Senior Vice
President of Market Access, will speak on panels addressing the
transformation of TB research and development (R&D) and the
accelerated rollout of TB drugs globally.
During the High-Level Meeting, Dr. Spigelman announced that TB
Alliance is pioneering a transformative "one by one" approach to TB
treatment: The goal is to treat latent TB infections in one day and
to treat active TB in one month. "This ambitious vision aims to
simplify TB care dramatically, making treatment faster and more
manageable for all people with TB," said Dr. Spigelman. Built on
the latest scientific breakthroughs, TB Alliance's vision offers a
path forward to not only contribute to the elimination of TB but to
ease the treatment journey for millions. "This isn't a far-off
dream," he continued. "It's a feasible goal grounded in today's
scientific advancements. We are working with new tools, promising
compounds, and novel approaches that are setting the stage for
faster, more effective treatments for both active and latent TB.
This approach has the potential to transform TB care globally, and
we're moving purposefully toward making it a reality for people
with TB everywhere."
With shorter treatment durations, a universal regimen, and
innovations that help simplify treatment – including once-daily
oral drugs, fixed-dose combinations, and long-acting injectables –
TB Alliance is following the science to find the next TB
therapies.
"Our mission to end TB demands innovation at every step. TB
Alliance's R&D strategy is focusing on identifying and
developing new cures that simplify treatment by making it shorter,
easier to administer, and more effective. Our objective is to save
lives by advancing science," said Dr. Eugene Sun. "With bold, people-centered
solutions, we can redefine what's possible in TB care and
accelerate the end of this devastating disease."
In recent years, TB Alliance's research and access strategies
have pioneered a paradigm shift in the global TB landscape, which
has made treatment breakthroughs possible and more accessible to
all who need them.
At today's event, Sandeep Juneja
underscored the critical role of early and deep collaboration with
high-burden countries, including Indonesia. "TB Alliance's access strategy has
reduced by 2/3rds, the time taken to provide widespread access to
life-saving treatments to communities in need. Working closely with
Indonesia and other high-burden
countries is essential to further speeding time to access and
accelerating the end of the TB pandemic," he said. "Together, we
are building a pathway to more equitable access to innovative,
ultra-short therapies of the future and making them available
faster than ever before."
This high-level meeting will serve as a crucial forum for
sharing insights, establishing cooperative frameworks, and
catalyzing actions that could accelerate the path to eliminating TB
worldwide. For TB Alliance, participation in this event reflects
its commitment to global collaboration in advancing not only
innovative treatments but also effective implementation and access
strategies that will ultimately help save millions of lives and
advance the fight against TB.
About TB
TB is a difficult infection to cure, requiring patients to take
a combination of medicines for at least four to six months. Even
after symptoms disappear, medicines still need to be taken so that
the disease can be fully eradicated. The scope and intensity of TB
globally is in large part fueled by antiquated and inadequate TB
drugs. Novel drug regimens are urgently needed to bring the TB
pandemic under control.
About TB Alliance
TB Alliance is a not-for-profit organization dedicated to
finding faster-acting and affordable drug regimens to fight TB.
Through innovative science and with partners around the globe, we
aim to ensure equitable access to faster, better TB cures that will
advance global health and prosperity. TB Alliance operates with
support from Australia's
Department of Foreign Affairs and Trade, Bill & Melinda Gates
Foundation, Foreign, Commonwealth and Development Office
(United Kingdom), Cystic Fibrosis
Foundation, Germany's Federal
Ministry of Education and Research through KfW, Global Disease
Eradication Fund (South Korea),
Global Health Innovative Technology Fund, Irish Aid, Korea International Cooperation
Agency, National Institute of Allergy and Infectious Diseases,
National Institutes of Health through the Congressionally Directed
Medical Research Programs, South
Korea's Ministry of Foreign Affairs, Unitaid, and the United
States Agency for International Development. For more information,
please visit: www.tballiance.org.
Media Contact: Jessica Wiggs,
communications@tballiance.org
Photo -
https://mma.prnewswire.com/media/2553095/TBAlliance_IndonesiaHLM.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/tb-alliance-joins-indonesias-high-level-meeting-on-tb-302300431.html